H.C. Wainwright Thinks Medivir AB’s Stock is Going to Recover

By Austin Angelo

In a report issued on February 26, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Medivir AB (MVRBFResearch Report), with a price target of SEK30.00. The company’s shares closed last Thursday at $0.96, close to its 52-week low of $0.86.

According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 39.7% and a 63.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.

Medivir AB has an analyst consensus of Moderate Buy, with a price target consensus of $3.56.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.85 and a one-year low of $0.86. Currently, Medivir AB has an average volume of 670.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Medivir AB is pharmaceutical research and development company. It develops pharmaceuticals for the treatment of cancer and specializes in protease inhibitor research and nucleotide science. The firm conducts research in all phases of pharmaceutical development from idea to clinical phase III studies. Its project pipeline includes Remetinostat, MIV-711, Birinapant, MIV-818, MIV-323 proprietary projects and also Olysio, JNJ-4178, Xerclear and MIV-802 partnership projects. The firm’s products include Xerclear and Simprevir.